Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taladegib · 1 trial · 1 indication
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which was determined by Dose-limiting toxicity (DLT). For the purpose of this study, the MTD was defined as the highest tested dose that had \<33% probability of causing a DLT in Cycle 1 of Part A.
| Arm | Type | Description |
|---|---|---|
| Taladegib | EXPERIMENTAL | Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle. Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle. Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors. Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC). |
| Name | Type | Description |
|---|---|---|
| Taladegib | DRUG | Administered IV |
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy. * Have the presence of measurable or nonmeasurable disease * Have...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Taladegib is an investigational small molecule being studied for the treatment of advanced cancer. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients with advanced cancer who are at least 18 years old.
Taladegib is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for advanced cancer.
Taladegib is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
Taladegib has been studied in one clinical trial, identified as NCT01226485, titled "A Study in Advanced Cancer." This was a Phase 1, uncontrolled trial conducted in the United States with 84 participants. The trial has been completed.
Taladegib is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for advanced cancer. The completed Phase 1 trial, NCT01226485, evaluated the drug in 84 patients, but no approval has been granted.